| __timestamp | Incyte Corporation | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 165772000 | 305409000 |
| Thursday, January 1, 2015 | 196614000 | 377080000 |
| Friday, January 1, 2016 | 303251000 | 432829000 |
| Sunday, January 1, 2017 | 366406000 | 496079000 |
| Monday, January 1, 2018 | 434407000 | 557616000 |
| Tuesday, January 1, 2019 | 468711000 | 658498000 |
| Wednesday, January 1, 2020 | 516922000 | 770456000 |
| Friday, January 1, 2021 | 739560000 | 840100000 |
| Saturday, January 1, 2022 | 1002140000 | 944700000 |
| Sunday, January 1, 2023 | 1161300000 | 1136600000 |
| Monday, January 1, 2024 | 1242157000 | 1464300000 |
Unleashing insights
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Vertex Pharmaceuticals Incorporated and Incyte Corporation have demonstrated distinct strategies in optimizing these costs. From 2014 to 2023, Vertex Pharmaceuticals saw a steady increase in SG&A expenses, peaking at approximately 1.14 billion in 2023. This represents a growth of nearly 270% from their 2014 figures. Incyte Corporation, on the other hand, experienced a more dramatic rise, with SG&A expenses surging by over 600% during the same period, reaching 1.16 billion in 2023.
While both companies have increased their spending, Vertex's more gradual approach suggests a focus on sustainable growth, whereas Incyte's rapid escalation may indicate aggressive expansion strategies. Understanding these trends provides valuable insights into how these biotech leaders navigate financial management in a dynamic industry.
Selling, General, and Administrative Costs: Pfizer Inc. vs Vertex Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Zoetis Inc.
Vertex Pharmaceuticals Incorporated and Teva Pharmaceutical Industries Limited: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Exelixis, Inc.
Operational Costs Compared: SG&A Analysis of Vertex Pharmaceuticals Incorporated and Opthea Limited
Cost Management Insights: SG&A Expenses for Vertex Pharmaceuticals Incorporated and Ultragenyx Pharmaceutical Inc.
Vertex Pharmaceuticals Incorporated and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Vertex Pharmaceuticals Incorporated or Arrowhead Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Vertex Pharmaceuticals Incorporated vs Viridian Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Incyte Corporation and Merus N.V.
Incyte Corporation vs Wave Life Sciences Ltd.: SG&A Expense Trends
Breaking Down SG&A Expenses: Incyte Corporation vs Xencor, Inc.